TY - JOUR AU - Cohen, H. T. AU - McGovern, F. J. PY - 2005 DA - 2005// TI - Renal-cell carcinoma JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMra043172 DO - 10.1056/NEJMra043172 ID - Cohen2005 ER - TY - JOUR AU - Law, T. M. AU - Motzer, R. J. AU - Mazumdar, M. PY - 1995 DA - 1995// TI - Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma JO - Cancer VL - 76 UR - https://doi.org/3.0.CO;2-N DO - 3.0.CO;2-N ID - Law1995 ER - TY - JOUR AU - Vogelzang, N. J. AU - Lipton, A. AU - Figlin, R. A. PY - 1993 DA - 1993// TI - Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial JO - J Clin Oncol VL - 11 ID - Vogelzang1993 ER - TY - JOUR AU - Motzer, R. J. AU - Bander, N. H. AU - Nanus, D. M. PY - 1996 DA - 1996// TI - Renal-cell carcinoma JO - N Engl J Med VL - 335 UR - https://doi.org/10.1056/NEJM199609193351207 DO - 10.1056/NEJM199609193351207 ID - Motzer1996 ER - TY - JOUR AU - Wilhelm, S. M. AU - Carter, C. AU - Tang, L. PY - 2004 DA - 2004// TI - BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis' JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-1443 DO - 10.1158/0008-5472.CAN-04-1443 ID - Wilhelm2004 ER - TY - JOUR AU - Ratain, M. J. AU - Eisen, T. AU - Stadler, W. M. PY - 2006 DA - 2006// TI - Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.03.6723 DO - 10.1200/JCO.2005.03.6723 ID - Ratain2006 ER - TY - JOUR AU - Escudier, B. AU - Eisen, T. AU - Stadler, W. M. PY - 2007 DA - 2007// TI - Sorafenib in advanced clear-cell renal-cell carcinoma JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa060655 DO - 10.1056/NEJMoa060655 ID - Escudier2007 ER - TY - JOUR AU - Bell, D. W. AU - Brannigan, B. W. AU - Matsuo, K. PY - 2008 DA - 2008// TI - Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-5030 DO - 10.1158/1078-0432.CCR-07-5030 ID - Bell2008 ER - TY - JOUR AU - Mu, X. L. AU - Li, L. Y. AU - Zhang, X. T. PY - 2005 DA - 2005// TI - Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2506 DO - 10.1158/1078-0432.CCR-04-2506 ID - Mu2005 ER - TY - JOUR AU - Weston, M. K. AU - Moss, D. P. AU - Stewart, J. PY - 2007 DA - 2007// TI - Differences in breast cancer biological characteristics between ethnic groups in New Zealand JO - Breast Cancer Res Treat VL - 111 UR - https://doi.org/10.1007/s10549-007-9813-3 DO - 10.1007/s10549-007-9813-3 ID - Weston2007 ER - TY - JOUR AU - Chen, P. AU - Aldape, K. AU - Wiencke, J. K. PY - 2001 DA - 2001// TI - Ethnicity delineates different genetic pathways in malignant glioma JO - Cancer Res VL - 61 ID - Chen2001 ER - TY - JOUR AU - Wiencke, J. K. AU - Aldape, K. AU - McMillan, A. PY - 2005 DA - 2005// TI - Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase JO - Cancer Epidemiol Biomarkers Prev VL - 14 UR - https://doi.org/10.1158/1055-9965.EPI-05-0089 DO - 10.1158/1055-9965.EPI-05-0089 ID - Wiencke2005 ER - TY - JOUR AU - Stafford, H. S. AU - Saltzstein, S. L. AU - Shimasaki, S. PY - 2008 DA - 2008// TI - Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival JO - J Urol VL - 179 UR - https://doi.org/10.1016/j.juro.2008.01.027 DO - 10.1016/j.juro.2008.01.027 ID - Stafford2008 ER - TY - CHAP AU - Greene, F. L. AU - Page, D. L. AU - Fleming, I. D. PY - 2002 DA - 2002// BT - American Joint Committee on Cancer (AJCC) Cancer Staging Manual PB - Springer-Verlag, Heidelberg New York CY - Berlin UR - https://doi.org/10.1007/978-1-4757-3656-4 DO - 10.1007/978-1-4757-3656-4 ID - Greene2002 ER - TY - JOUR AU - Kaplan, E. L. AU - Meier, P. PY - 1958 DA - 1958// TI - Nonparametric estimation from incomplete observations JO - J Am Stat Assoc VL - 53 UR - https://doi.org/10.1080/01621459.1958.10501452 DO - 10.1080/01621459.1958.10501452 ID - Kaplan1958 ER - TY - JOUR AU - Flaherty, K. T. PY - 2007 DA - 2007// TI - Sorafenib in renal cell carcinoma JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2063 DO - 10.1158/1078-0432.CCR-06-2063 ID - Flaherty2007 ER - TY - JOUR AU - Thatcher, N. AU - Chang, A. AU - Parikh, P. PY - 2005 DA - 2005// TI - Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) JO - Lancet VL - 366 UR - https://doi.org/10.1016/S0140-6736(05)67625-8 DO - 10.1016/S0140-6736(05)67625-8 ID - Thatcher2005 ER - TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040938 DO - 10.1056/NEJMoa040938 ID - Lynch2004 ER - TY - JOUR AU - Uramoto, H. AU - Sugio, K. AU - Oyama, T. PY - 2006 DA - 2006// TI - Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese JO - Lung Cancer VL - 51 UR - https://doi.org/10.1016/j.lungcan.2005.08.006 DO - 10.1016/j.lungcan.2005.08.006 ID - Uramoto2006 ER - TY - JOUR AU - Bellmunt, J. AU - González-Larriba, J. L. AU - Climent, M. A. PY - 2007 DA - 2007// TI - Sorafenib TARGET trial results in Spanish patients JO - Clin Transl Oncol VL - 9 UR - https://doi.org/10.1007/s12094-007-0120-6 DO - 10.1007/s12094-007-0120-6 ID - Bellmunt2007 ER - TY - JOUR AU - Akaza, H. AU - Tsukamoto, T. AU - Murai, M. PY - 2007 DA - 2007// TI - Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma JO - Jpn J Clin Oncol VL - 37 UR - https://doi.org/10.1093/jjco/hym095 DO - 10.1093/jjco/hym095 ID - Akaza2007 ER - TY - JOUR AU - Escudier, B. AU - Lassau, N. AU - Angevin, E. PY - 2007 DA - 2007// TI - Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-1432 DO - 10.1158/1078-0432.CCR-06-1432 ID - Escudier2007 ER - TY - JOUR AU - Gollob, J. A. AU - Rathmell, W. K. AU - Richmond, T. M. PY - 2007 DA - 2007// TI - Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.10.8613 DO - 10.1200/JCO.2007.10.8613 ID - Gollob2007 ER - TY - JOUR AU - Ryan, C. W. AU - Goldman, B. H. AU - Lara, P. N. PY - 2007 DA - 2007// TI - Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.11.1047 DO - 10.1200/JCO.2007.11.1047 ID - Ryan2007 ER - TY - JOUR AU - Drevs, J. AU - Konerding, M. A. AU - Wolloscheck, T. PY - 2004 DA - 2004// TI - The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma JO - Angiogenesis VL - 7 UR - https://doi.org/10.1007/s10456-005-1394-3 DO - 10.1007/s10456-005-1394-3 ID - Drevs2004 ER - TY - JOUR AU - Drevs, J. AU - Hofmann, I. AU - Hugenschmidt, H. PY - 2584 DA - 2584// TI - Effects of PTK787/ZK 22 a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model JO - Cancer Res VL - 60 ID - Drevs2584 ER - TY - JOUR AU - Karpanen, T. AU - Egeblad, M. AU - Karkkainen, M. J. PY - 2001 DA - 2001// TI - Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth JO - Cancer Res VL - 61 ID - Karpanen2001 ER - TY - JOUR AU - Flanigan, R. C. AU - Salmon, S. E. AU - Blumenstein, B. A. PY - 2001 DA - 2001// TI - Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer JO - N Engl J Med VL - 345 UR - https://doi.org/10.1056/NEJMoa003013 DO - 10.1056/NEJMoa003013 ID - Flanigan2001 ER - TY - JOUR AU - Strumberg, D. AU - Awada, A. AU - Hirte, H. PY - 2006 DA - 2006// TI - Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: Is rash associated with treatment outcome? JO - Euro J Cancer VL - 42 UR - https://doi.org/10.1016/j.ejca.2005.11.014 DO - 10.1016/j.ejca.2005.11.014 ID - Strumberg2006 ER - TY - JOUR AU - Cheng, A. L. AU - Kang, Y. K. AU - Chen, Z. PY - 2009 DA - 2009// TI - Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(08)70285-7 DO - 10.1016/S1470-2045(08)70285-7 ID - Cheng2009 ER - TY - JOUR AU - Llovet, J. M. AU - Ricci, S. AU - Mazzaferro, V. PY - 2008 DA - 2008// TI - Sorafenib in advanced hepatocellular carcinoma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708857 DO - 10.1056/NEJMoa0708857 ID - Llovet2008 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/249/prepub UR - http://www.biomedcentral.com/1471-2407/9/249/prepub ID - ref32 ER -